Proactive management of EGFR-mediated toxicities can help to prevent the escalation of grade 1/2 skin toxicities to higher-grade events.
Pavlos Msaouel, MD, PhD
Advertisement
Articles by Pavlos Msaouel, MD, PhD
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5